Emerging research is highlighting a potential connection between GLP-1 medications and a decreased risk of certain cancers, particularly as semaglutide becomes increasingly accessible in Canada, with affordable generic options now reaching local pharmacies. These findings were unveiled at the recent American Society of Clinical Oncology conference in Chicago, where over two dozen studies indicated that patients using GLP-1 drugs exhibited lower cancer incidence, enhanced survival rates, and improved treatment responses compared to non-users.
Promising Findings from Recent Studies
Dr. Judith Bray, Vice-President of Research at the Canadian Cancer Society, expressed optimism about the implications of this research, labelling it “transformative.” She noted, “For over a year, we’ve had whispers of these possibilities, and now the entire research community is taking notice.”
One significant study presented at the conference, conducted by the ESMO Annals of Oncology, analysed data from more than 161,000 patients, averaging 47 years old, who were either classified as obese or had not been diagnosed with obesity-related cancers. Among these participants, half received GLP-1 injectable therapies, while the other half were given advice on diet and exercise over a two-year follow-up period. The results were striking: those on GLP-1 medications showed a remarkable 41% reduction in the likelihood of developing obesity-related cancers during the study.
Links Between GLP-1 Usage and Breast Cancer Prevention
A separate study published on June 2 in JCO Oncology Practice further examined the relationship between GLP-1 treatments and breast cancer risks. This research identified over 110,000 women aged 45 to 80 who underwent breast imaging from January 1, 2022, to June 30, 2025. Findings revealed that 14% of the women had been prescribed GLP-1 medications. Notably, those using these drugs experienced a 35% lower risk of developing breast cancer compared to non-users. When researchers matched over 15,000 GLP-1 users with women of similar profiles not using the medication, the odds of breast cancer were reduced by nearly 31%.
Lead researcher Dr. Elizabeth McDonald emphasised the need for further investigation, stating, “While our study is observational and does not definitively confirm an association between GLP-1 medications and reduced breast cancer incidence, it contributes to the growing evidence base suggesting these weight-loss drugs could play a role in cancer prevention.”
The Need for Canadian Research
Breast cancer is projected to be the most commonly diagnosed cancer among women in Canada by 2026, according to the Canadian Medical Association Journal, accounting for 26% of cases and remaining a leading cause of cancer-related mortality. In light of this alarming statistic, Kimberly Carson, CEO of Breast Cancer Canada, hailed the new research as “very encouraging,” expressing hope that it could pave the way for future cancer prevention strategies.
Carson stressed the importance of further Canadian research in this area, saying, “We currently lack Canadian data, and I believe there is a significant opportunity for studies like these to be conducted here.” She underscored that Canada has the capacity to make valuable contributions to this burgeoning field of research.
Why it Matters
The potential link between GLP-1 medications and cancer risk reduction could herald a significant shift in how we approach obesity management and cancer prevention. With obesity rates rising in Canada—where 68% of adults aged 18 to 79 are now classified as overweight or obese—understanding the broader health implications of weight-loss drugs is crucial. As more studies emerge, there is hope that these findings will not only inform clinical practices but also offer new avenues for preventive healthcare, ultimately saving lives and reducing the burden of cancer in our society.
